How will QTTB's EPS perform in Q1 2025?

QTTB's EPS is expected to face significant challenges in Q1 2025. Here's a detailed analysis:

1. Current Estimates: There are no available estimates for QTTB's EPS in Q1 2025.
2. Recent Performance: QTTB's EPS for the previous quarter (Q4 2024) was reported at ($1.42), which missed analysts' consensus estimates of ($1.00) by ($0.42).
3. Analyst Ratings and Trends: The stock has a Moderate Buy rating with 7 analysts rating it as 4 Buy, 3 Hold, and 0 Sell. The average price target for QTTB is $18.17, with a high forecast of $22.00 and a low forecast of $9.00. This suggests that while there is potential for growth, the EPS may not yet be aligned with these expectations.

4. Institutional Activity: Institutional investors have shown interest, with some increasing their holdings. For example, Ensign Peak Advisors Inc raised its position by 150.6% during Q2 2024, and Bank of New York Mellon Corp acquired a new position in Q2 2024. However, these increases in institutional holdings do not provide direct insight into QTTB's EPS performance.
5. Market Capitalization and Financial Ratios: QTTB has a market capitalization of $549.33 million as of the latest data, with a P/E ratio of -1.41, indicating that the company is not profitable as of the last report. The company's current ratio and quick ratio are both 6.49, suggesting good liquidity, which is positive for operational stability but does not directly impact EPS.
6. Future Outlook: The consensus estimate for Q32 Bio's current full-year earnings is ($10.85) per share, which is a broader view and does not specifically address Q1 2025. However, the estimates for Q2 2024 earnings at ($0.93) EPS, Q3 2024 earnings at ($0.99) EPS, and Q4 2024 earnings at ($1.05) EPS suggest a potential improvement trajectory, which could imply that QTTB's EPS may show improvement in subsequent quarters.

In conclusion, while there is some optimism based on analyst ratings and institutional investments, the lack of specific EPS estimates for Q1 2025 and the current unprofitable state of the company suggest that significant challenges may persist in the upcoming quarter.